Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

May 15, 2025
Alfresa Holdings Corporation

Notice Regarding Election of Director Candidates Due to Transition to a Company with Audit and Supervisory Committee Structure and Changes to Executive Personnel

As disclosed in our notice dated February 26, 2025, "Notice Regarding Transition to a Company with Audit and Supervisory Committee Structure," we are planning transition from a company with audit and supervisory board structure to a company with audit and supervisory committee structure, subject to approval at the 22nd Ordinary General Meeting of Shareholders scheduled in June 25, 2025.

In line with this transition, during today's board of directors meeting we have resolved on director candidates to be proposed at the 22nd Ordinary General Meeting of Shareholders and decided on changes to executive personnel, which we hereby announce as follows.

1. Candidates for Directors (excluding directors who are Audit and Supervisory Committee Members)

New title	Current title	Name
Representative Director & President	Same as left	Ryuji Arakawa
Representative Director & Executive Vice President, Ethical Pharmaceuticals Wholesaling Business & International Business	Same as left	Yusuke Fukujin
Director, Vice President & Executive Officer, Group Business Strategy (In charge of Group Business Planning, Total Supply Chain Services Business Planning)	Same as left	Shigeki Ohashi
Director, Vice President & Executive Officer, Corporate Administration (In charge of General Affairs, Financial Planning, Corporate Communication)	Same as left	Toshiki Tanaka

Director	Same as left	Koichi Shimada
Outside Director	Same as left	Manabu Kinoshita
Outside Director	Same as left	Toshie Takeuchi
Outside Director	Same as left	Kimiko Kunimasa

2. Candidates for Directors who are Audit and Supervisory Committee Members

New title	Current title	Name
Director (Audit and Supervisory Committee Member)	Full-time Audit and Supervisory Board Member	Yuji Ueda
Outside Director (Audit and Supervisory Committee Member)	Outside Audit and Supervisory Board Member	Takashi Ito
Outside Director (Audit and Supervisory Committee Member)	Outside Audit and Supervisory Board Member	Hiroshi Kizaki
Outside Director (Audit and Supervisory Committee Member)	—	Sachiko Iizuka

Note:
Sachiko Iizuka is currently serving as Representative Director of LAULEA CORPORATION, Outside Auditor of BeeX Co., Ltd., Representative Partner of Cenxus Audit Corporation, and Outside Director (Audit and Supervisory Committee Member) of Net One Systems Co., Ltd.

3. Director scheduled to retire(As of June 25, 2025)

Current title	Name
Director	Seiichi Kishida
Director	Hisashi Katsuki
Outside Director	Takashi Hara

Note:
Effective May 28, 2025, Hisashi Katsuki will assume the post of Corporate Adviser of Alfresa Healthcare Corporation.

4. Audit & Supervisory Board Member scheduled to retire(As of June 25, 2025)

Current title	Name
Full-time Audit and Supervisory Board Member	Masakazu Ozaki

Full-time Audit and Supervisory Board Member	Yuji Ueda
Outside Audit and Supervisory Board Member	Yoshitaka Kato
Outside Audit and Supervisory Board Member	Takashi Ito
Outside Audit and Supervisory Board Member	Hiroshi Kizaki

Notes:
1. Effective June 17, 2025, Masakazu Ozaki will assume the post of Full-time Audit and Supervisory Board Member of Alfresa Corporation.
2. Yuji Ueda is candidate for a Director who is an Audit and Supervisory Committee Member.
3. Takashi Ito and Hiroshi Kizaki are candidates for Outside Directors who are Audit and Supervisory Committee Members.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.9 trillion for the fiscal year ended March 31, 2025. For more information, please see: https://www.alfresa.com/eng/